Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Structure Therapeutics Inc. - American Depositary Shares (NQ:GPCR)

25.57 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Structure Therapeutics Inc. - American Depositary Shares

< Previous 1 2 3 4 5 Next >
Fox, Warner Music, Eli Lilly, Chegg And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded lower, with the Dow Jones falling around 400 points on Tuesday. Here are some big stocks recording gains in today’s session. Paymentus Holdings, Inc. (NYSE: PAY) shares rose 29.4% to... 
Via Benzinga
Structure Therapeutics Appoints Ted W. Love, M.D., to Board of Directors
From Structure Therapeutics Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For July 27, 2023
Via Benzinga
The Blazing Weight-Loss Drug Battle: Can Anyone Unseat Undisputed Leaders Novo Nordisk And Lilly?
An overweight world is hungry for new treatments. For now, two companies own the market. 
Via Investor's Business Daily
Why Shares of Structure Therapeutics Rose Monday
The company's lead diabetes and weight-loss therapy may benefit from a decision by Pfizer. 
Via The Motley Fool
Wolfspeed, Genesco, PacWest Bancorp And Other Big Stocks Moving Higher On Monday
U.S. stocks traded mixed, with the Nasdaq Composite gaining around 60 points on Monday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Cava Stock Makes A Stand In Mixed IPO Landscape: Where Does It Rank Against Other 2023 Wall Street Debuts?
In a year that’s seen a sharp decline in initial public offerings, Washington, D.C.-based Mediterranean restaurant chain Cava Group (NYSE: CAVA) made a striking first public appearance on the New York... 
Via Benzinga
This Biotech Is Developing The Next Ozempic. Should You Buy It?
If it succeeds, it'll still face a battle for market share. 
Via The Motley Fool
Buying Shares of These 2 Biotech Stocks Could Be a Brilliant Move in 5 Years
If you can tolerate the risk and have some patience, both stocks could blossom. 
Via The Motley Fool
Structure Therapeutics Announces Poster Presentations of its Oral GLP-1 Receptor Agonist GSBR-1290 at the American Diabetes Association 83rd Scientific Sessions
From Structure Therapeutics Inc.
Via GlobeNewswire
Structure Therapeutics to Present at Jefferies Healthcare Conference
From Structure Therapeutics Inc.
Via GlobeNewswire
Booz Allen Hamilton, Workday, Marvell Technology And Other Big Stocks Moving Higher On Friday
U.S. stocks traded higher, with the Dow Jones gaining over 300 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Why Hibbett Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Onfolio Holdings, Inc. (NASDAQ: ONFO) gained 73% to $2.02 after the company announced it completed development of a generative AI search tool. 
Via Benzinga
Structure Therapeutics Initiates Phase 2a Study of Oral GLP-1 agonist GSBR-1290 for the Treatment of Type 2 Diabetes and Obesity
From Structure Therapeutics Inc.
Via GlobeNewswire
Structure Therapeutics Announces Poster Presentations at the American Thoracic Society International Conference
Posters include data across biomarker, translation and clinical studies supporting development of cardiopulmonary programs LTSE-2578 and ANPA-0073 
From Structure Therapeutics Inc.
Via GlobeNewswire
Structure Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights
From Structure Therapeutics Inc.
Via GlobeNewswire
Structure Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights
From Structure Therapeutics Inc.
Via GlobeNewswire
Analysts Sees Over 50% Upside Opportunity For This Newly Listed Obesity Player Stock, Participating In Big Pharma Race
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 28, 2023
Via Benzinga
There's a Lot to Love About Mineralys' Valentine's Day IPO
MLYS added 20% more shares to IPO funding, which goes live on 2/14. The bump secured liquidity to stabilize development, improving market cap to $683 million 
Via MarketBeat
Topics Initial Public Offering
Exposures Securities Market
Structure Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional American Depositary Shares
From Structure Therapeutics Inc.
Via GlobeNewswire
Week In Review: Structure Stages $161 Million US IPO For AI/Structure-Based Drug Development
Structure Therapeutics raised $161 million in a successful US IPO to support development of its oral therapeutics portfolio aimed at chronic metabolic and pulmonary diseases. Schrödinger is a... 
Via Talk Markets
Dow Drops Over 150 Points; US economy Adds 517,000 Jobs In January
U.S. stocks traded lower, with the Dow Jones dropping over 150 points on Friday. The Dow traded down 0.51% to 33,881.69 while the NASDAQ fell 1.32% to 12,039.79. The S&P 500 also fell, dropping, 0.98%... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.